UPDATE
Genzyme to strengthen Fabrazyme production with $80m downstream plant
Genzyme says it will invest $80m (€59m) in a new downstream plant to process its Fabry Disease drug, Fabrazyme.
Archives for October 15, 2013
report from Biotechnica
Better single-use cross flow techs still needed says GE Healthcare
The biopharmaceutical manufacturing sector needs better cross flow filtration technologies according to GE Healthcare, which says that advances in bioreactor systems have not been matched downstream.
Dr Reddy’s looks to bring biosimilars to EU within five years
With in-house production and manufacturing capacity, as well as a deal with Merck Serono, India-based generics giant Dr. Reddy’s is looking to bring as many as four biosimilars to the EU market by 2019.
Dispatches from Biotechnica
Brain AG wins award for furthering industrial biotech
Biocatalyst and microbial strain developer Brain AG was recognised for furthering industrial use of biotechnology in a ceremony at the Biotechnica trade show in Hanover, Germany yesterday.
Cali Gov vetoes biosimilar bill, thwarting Amgen and Genentech
The Governor of California has vetoed a bill set to constrict the dispensing of biosimilars due to its premature nature, much to the disappointment of Amgen and Genentech.
Good news CMOs: Roche will still outsource after $877m biologics investment
Roche will continue to work with biologics CMOs despite its plans to spend CHF800m ($877m) on additional in-house production and development capacity.